The 1st European Conference: Perspectives in Melanoma Management

Last Modified: July 6, 2003

Conference Dates: October 9-11, 2003
Conference Location: Amsterdam, The Netherlands


Sponsoring Group: Imedex. Under the auspices of EORTC

Conference Web Page URL: www.imedex.com/announcements/emelanoma03.html

Topics Covered: EORTC Melanoma Group Program Scientific Reports, Phase III Trials in Stage IV Melanoma, Vaccine Development in Melanoma, What Next: New Drugs in First Line in Stage IV Melanoma, Genetic Epidemiology, Sentinel Node and Other Prognostic Factors, Adjuvant Therapy of Melanoma Interferons, Vaccines

Conference Objectives: The objective of this meeting is to present and evaluate the most recent developments in the management of melanoma. The presentations and discussions will focus on adjuvant chemotherapy, vaccine development, genetic epidemiology, the role of sentinel node and other prognostic factors in melanoma.

Who Should Attend: This educational program is intended for oncologists, dermatologists, and other physicians in active clinical practice interested and/or involved in the management of melanoma. No specific knowledge or skills other than a general familiarity with medical oncology and/or dermatology for successful participation in this program.

Registration Information: Online at www.imedex.com ; call Imedex at +1 (770) 751 7332 or fax to +1 770-751-7334

Conference Fees: Early (by June 30) ? 299, Regular (by September 29) ? 399, Full (after September 29 and onsite) ? 499. EORTC Member discount ? 100, ESMO Member discount ? 50.

Continuing Education: Yes

Miscellany: submitted to ESMO for accreditation. Participants will receive a certificate of attendance at the end of the conference.

Blogs

Don't Assume You Understand
by Bob Riter
July 29, 2015

Related News

Age-Linked Variation Noted in Melanoma Management

Aug 16, 2013

Older patients more likely to have thicker, ulcerated tumors; less likely to receive adjuvant tx


AACR: Conference Offers Look at Cancer Drugs in Pipeline

Jul 31, 2015

International conference presentations include leukemia drug screening, olaparib, cediranib


Biopsy-Based Management Improves Melanoma Outcomes

Feb 14, 2014

Sentinel-node biopsy-based management ups outcomes for intermediate thickness, thick melanomas